ES2515168T3 - Detección y tratamiento de la esquizofrenia - Google Patents
Detección y tratamiento de la esquizofrenia Download PDFInfo
- Publication number
- ES2515168T3 ES2515168T3 ES08792016.1T ES08792016T ES2515168T3 ES 2515168 T3 ES2515168 T3 ES 2515168T3 ES 08792016 T ES08792016 T ES 08792016T ES 2515168 T3 ES2515168 T3 ES 2515168T3
- Authority
- ES
- Spain
- Prior art keywords
- schizophrenia
- treatment
- detection
- pyridoxamine
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Abstract
Piridoxamina o una sal farmacéuticamente aceptable de la misma para la utilización en la mejora de la esquizofrenia o el tratamiento de un paciente con esquizofrenia.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007214047 | 2007-08-20 | ||
JP2007214047A JP5288365B2 (ja) | 2007-07-17 | 2007-08-20 | 統合失調症の検査および治療 |
PCT/JP2008/063803 WO2009025159A1 (ja) | 2007-08-20 | 2008-07-31 | 統合失調症の検査および治療 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2515168T3 true ES2515168T3 (es) | 2014-10-29 |
Family
ID=40378067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08792016.1T Active ES2515168T3 (es) | 2007-08-20 | 2008-07-31 | Detección y tratamiento de la esquizofrenia |
Country Status (11)
Country | Link |
---|---|
US (2) | US8809329B2 (es) |
EP (2) | EP2662453A3 (es) |
JP (1) | JP5288365B2 (es) |
CY (1) | CY1115640T1 (es) |
DK (1) | DK2189537T3 (es) |
ES (1) | ES2515168T3 (es) |
HR (1) | HRP20140993T1 (es) |
PL (1) | PL2189537T3 (es) |
PT (1) | PT2189537E (es) |
SI (1) | SI2189537T1 (es) |
WO (1) | WO2009025159A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2441764B1 (en) | 2009-06-12 | 2017-03-22 | Bioneer Corporation | Use of 4-methylenyl-5-oxo-1,5-dihydro-4H-pyrazol, 5-methylenyl-5H-cyclopenta[b]pyridine and pyrimidine-2,4,6(1H,3H,5H)-trione derivatives and related compounds for RNAase inhibition in RNA sample storage containers |
JP5840124B2 (ja) * | 2010-05-14 | 2016-01-06 | 公益財団法人東京都医学総合研究所 | 統合失調症の検出方法 |
CN102993191B (zh) * | 2012-12-18 | 2015-05-27 | 苏州大学 | 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途 |
EP3187185A4 (en) | 2014-08-29 | 2018-04-11 | Project PM Co., Ltd. | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound |
KR101796391B1 (ko) * | 2015-07-24 | 2017-11-09 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
JP6105111B1 (ja) * | 2016-03-02 | 2017-03-29 | 国立大学法人東北大学 | 自閉スペクトラム症改善用組成物 |
JP6924964B2 (ja) * | 2017-07-07 | 2021-08-25 | パナソニックIpマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
WO2019008996A1 (ja) * | 2017-07-07 | 2019-01-10 | パナソニックIpマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
WO2019008981A1 (ja) * | 2017-07-07 | 2019-01-10 | パナソニックIpマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
US11932880B2 (en) | 2018-02-27 | 2024-03-19 | Kikkoman Corporation | Enzyme and method for assaying pentosidine using same |
EP4023754A4 (en) * | 2019-08-27 | 2023-09-27 | Kikkoman Corporation | METHOD FOR MEASURING PENTOSIDINE AND MEASURING KIT |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52102431A (en) * | 1976-02-25 | 1977-08-27 | Kyowa Hakko Kogyo Co Ltd | Remedies for mental disorder |
JP3507884B2 (ja) * | 2000-03-07 | 2004-03-15 | 新潟大学長 | 遺伝子発現を指標とする統合失調症の客観的診断法 |
ATE389014T1 (de) * | 2001-01-31 | 2008-03-15 | Vlaams Interuniv Inst Biotech | Phosphorylierte glyoxalase i und deren verwendung |
JP2003038198A (ja) | 2001-07-27 | 2003-02-12 | Univ Niigata | 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法 |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
JP2003212795A (ja) | 2002-01-15 | 2003-07-30 | Japan Science & Technology Corp | 精神分裂病の診断薬 |
EP1542017A4 (en) | 2002-07-04 | 2007-07-11 | Mitsubishi Pharma Corp | METHOD FOR EXAMINING AND DIAGNOSING THE INTEGRATION ERROR SYNDROME |
JP2004251865A (ja) | 2003-02-19 | 2004-09-09 | Takashi Muramatsu | 統合失調症およびアルツハイマー病の検査薬 |
JP4143498B2 (ja) | 2003-07-31 | 2008-09-03 | 独立行政法人科学技術振興機構 | 統合失調症の判定方法 |
TW200524929A (en) | 2003-09-30 | 2005-08-01 | Sankyo Co | Phenylene derivatives having tetrazole ring or thiazolidinedione ring |
US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
AU2004294435B2 (en) | 2003-12-05 | 2010-07-08 | Kiyoshi Kurokawa | Inhibitor of protein modification products formation |
JP2005278490A (ja) | 2004-03-29 | 2005-10-13 | Japan Science & Technology Agency | 統合失調症に関与する生物学的マーカーの判定方法およびその利用 |
US20100137635A1 (en) * | 2005-06-07 | 2010-06-03 | Inbiotex Inc. | Radical scavenger and active oxygen eliminating agent |
TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
-
2007
- 2007-08-20 JP JP2007214047A patent/JP5288365B2/ja not_active Expired - Fee Related
-
2008
- 2008-07-31 EP EP20130003496 patent/EP2662453A3/en not_active Withdrawn
- 2008-07-31 DK DK08792016.1T patent/DK2189537T3/da active
- 2008-07-31 PL PL08792016T patent/PL2189537T3/pl unknown
- 2008-07-31 WO PCT/JP2008/063803 patent/WO2009025159A1/ja active Application Filing
- 2008-07-31 EP EP08792016.1A patent/EP2189537B1/en active Active
- 2008-07-31 ES ES08792016.1T patent/ES2515168T3/es active Active
- 2008-07-31 US US12/674,018 patent/US8809329B2/en active Active
- 2008-07-31 PT PT87920161T patent/PT2189537E/pt unknown
- 2008-07-31 SI SI200831305T patent/SI2189537T1/sl unknown
-
2014
- 2014-07-08 US US14/325,808 patent/US20140335517A1/en not_active Abandoned
- 2014-10-10 CY CY20141100824T patent/CY1115640T1/el unknown
- 2014-10-16 HR HRP20140993AT patent/HRP20140993T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI2189537T1 (sl) | 2014-11-28 |
JP2009039088A (ja) | 2009-02-26 |
HRP20140993T1 (hr) | 2014-12-19 |
US20110028470A1 (en) | 2011-02-03 |
US20140335517A1 (en) | 2014-11-13 |
JP5288365B2 (ja) | 2013-09-11 |
EP2662453A2 (en) | 2013-11-13 |
PL2189537T3 (pl) | 2015-01-30 |
US20120065198A2 (en) | 2012-03-15 |
DK2189537T3 (da) | 2014-10-27 |
US8809329B2 (en) | 2014-08-19 |
EP2189537B1 (en) | 2014-10-08 |
EP2189537A1 (en) | 2010-05-26 |
WO2009025159A1 (ja) | 2009-02-26 |
CY1115640T1 (el) | 2017-01-04 |
PT2189537E (pt) | 2014-10-30 |
EP2189537A4 (en) | 2010-08-11 |
EP2662453A3 (en) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2515168T3 (es) | Detección y tratamiento de la esquizofrenia | |
ES2545205T3 (es) | Combinación de azelastina y ciclesonida | |
ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
ES2509117T3 (es) | Composición farmacéutica oral que contiene dabigatran etexilato | |
ES2644750T3 (es) | Gaviones | |
ES2505643T3 (es) | Galectina para uso en el tratamiento del síndrome del ojo seco | |
ES2500067T3 (es) | Compuesto bicíclico y uso del mismo para fines médicos | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
ES2523968T3 (es) | Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas | |
CL2007001902A1 (es) | Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas. | |
JP2007527914A5 (es) | ||
CO6491052A2 (es) | Compuestos espirociclicos que contienen notrogeno y su uso medicinal | |
ECSP088555A (es) | Composiciones farmacéuticas | |
ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
ECSP099629A (es) | Composición farmacéutica | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
CO6321285A2 (es) | Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria | |
CL2007003444A1 (es) | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. | |
JP2009536652A5 (es) | ||
ES2633762T3 (es) | Hipertensión e hiperuricemia | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
ES2496669T3 (es) | Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen | |
ES2527454T3 (es) | El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico | |
ES2534911T3 (es) | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |